BUZZ - Insmed shares fall as CFO Sara Bonstein resigns

路透社2026/10/05 11:46

Show original

October 5 - ** Shares of pharmaceutical company Insmed (INSM.O) fell more than 3% in pre-market trading to $107.59. ** Sara Bonstein will resign from her position as Chief Financial Officer, effective October 30. ** Sara will stay on until the end of this month to ensure a smooth transition during the company's release of its Q3 financial results on October 29. ** Before joining Insmed, Sara served as Chief Financial Officer at OncoSec Medical. ** The company reaffirmed its fiscal 2026 performance guidance and has begun the search for the next Chief Financial Officer. ** All 25 brokerages covering the stock remain bullish; the median target price is compiled by LSEG data. ** As of the close of the previous trading day, the stock was down 36.15% year-to-date. (To assist non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the translated text and provides automated translation solely for reader convenience. Reuters accepts no liability for any damage or losses caused by the use of automated translation functionality.)

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

October 5 - ** The share price of pharmaceutical company Insmed (INSM.O) fell more than 3% in pre-market trading to $107.59

** Sara Bonstein will resign as Chief Financial Officer, effective October 30

** Sara will remain until the end of this month to ensure a smooth transition during the company's third quarter earnings release on October 29

** Prior to joining Insmed, Sara served as Chief Financial Officer of OncoSec Medical

** The company reaffirmed its fiscal year 2026 guidance and has begun the search for the next Chief Financial Officer

** All 25 brokerages covering the stock are bullish; the median target price — data compiled by LSEG

** As of the close of the last trading day, the stock was down 36.15% year-to-date

(To facilitate non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translation may contain errors or may lack necessary context, Reuters does not guarantee the accuracy of the automated translation text and provides it solely for the convenience of readers. Reuters assumes no liability for any damage or loss caused by the use of the automated translation function.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

11:12 AM EDT, 10/05/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts opened the week lower late Monday morning, declining 0.14% to 1,883.96 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by lender Banco Santander (SAN) and brewing company Anheuser-Busch InBev (BUD), which advanced 3.2% and 0.8% respectively. They were followed by 3D printer company Materialise (MTLS) and internet browser company Opera (OPRA), which were up 0.6% and 0.3% respectively. The decliners from continental Europe were led by biopharmaceutical company Nokia (NOK) and biopharmaceutical company Cellectis (CLLS), which lost 3.2% each. They were followed by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which decreased 0.9% and 0.4%, respectively. The gainers from the UK were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and software firm Endava plc (DAVA), which climbed 17% and 1.6% respectively. They were followed by medical device maker Smith & Nephew (SNN) and biotech firm Trinity Biotech (TRIB), which increased 1.2% and 1.4% respectively. The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 3.9% and 1.4% respectively. They were followed by hospitality company InterContinental Hotels Group (IHG) and pharmaceutical company GSK (GSK), which fell 1.1% and 1% respectively.

MT newswire•2026/10/05 15:12

Bitcoin Returns Reliant on Major Days -- Market Talk

1105 ET - Bitcoin's strong year-over-year returns are more linked to single days of strong moves, according to Zach Pandl of Grayscale in a note. Pandl says removing bitcoin's five best trading days reduces its three-year return from 225% to 95%, with the return falling to 27% without its 10 best days. If you remove the top fifteen days, it turns a three-year gain into an 11% loss. By comparison, removing the Nasdaq's fifteen best days reduces its cumulative return from 109% to 21%. "Given BTC's return and volatility profile, investors looking for long-term capital appreciation can avoid trying to time the market and instead seek consistent, long-term exposure to the asset," Pandl says. Bitcoin is down 0.2% to $85,610, while ethereum falls 0.2% to $2,701. (kirk.maltais@wsj.com) (END) Dow Jones Newswires October 05, 2026 11:05 ET (15:05 GMT)

Dow Jones•2026/10/05 15:05